$760k per Cd17 CarT patients treatment. They need at least another patients data before any BP deal can be made (see announcements from a couple of days ago). CHM is approaching a massive pivot. But it needs cash to push on through this point.
Without cash, the Cd17 CarT can't be progressed. Without it progressing, your investment stagnates and becomes worthless.
This is a very high-risk play. It's investigating a novel cancer treatment, and this is a very expensive treatment to get to hit arms. CHM is attempting to get the next cohort of patients treated with the hope that this will provide enough data to get a BP partner to look after costs in the future.
It also has the NK cells and GBM drugs. NK seems to be kicking goals, as seen yesterday.
Very high risk. This isn't an investment for everyone, but potential, even with dilution, is huge.
CHM Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)